Saundra S. Buys
A5075169712- BRCA gene mutations in cancer
- Cancer Risks and Factors
- Nutrition, Genetics, and Disease
- Nutritional Studies and Diet
- Ovarian cancer diagnosis and treatment
- Genetic Associations and Epidemiology
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Global Cancer Incidence and Screening
- Genomic variations and chromosomal abnormalities
- Breast Cancer Treatment Studies
- Physical Activity and Health
- DNA Repair Mechanisms
- Genetics, Bioinformatics, and Biomedical Research
- CRISPR and Genetic Engineering
- Colorectal Cancer Screening and Detection
- RNA modifications and cancer
- Estrogen and related hormone effects
- Ubiquitin and proteasome pathways
- Childhood Cancer Survivors' Quality of Life
- Endometrial and Cervical Cancer Treatments
- Genomics and Chromatin Dynamics
- Prostate Cancer Treatment and Research
- Prenatal Screening and Diagnostics
- Obesity, Physical Activity, Diet
University of Utah
2016-2025
Huntsman Cancer Institute
2016-2025
National Cancer Institute
2000-2020
Cancer Clinic
2020
Zero to Three
2017
Wellcome Sanger Institute
2017
Sapienza University of Rome
2017
Oregon Health & Science University
2017
University of Pennsylvania
2014-2016
Georgetown University
2009-2016
The effect of screening with prostate-specific–antigen (PSA) testing and digital rectal examination on the rate death from prostate cancer is unknown. This first report Prostate, Lung, Colorectal, Ovarian (PLCO) Cancer Screening Trial prostate-cancer mortality.
<h3>Importance</h3> The clinical management of<i>BRCA1</i>and<i>BRCA2</i>mutation carriers requires accurate, prospective cancer risk estimates. <h3>Objectives</h3> To estimate age-specific risks of breast, ovarian, and contralateral breast for mutation to evaluate modification by family history location. <h3>Design, Setting, Participants</h3> Prospective cohort study 6036<i>BRCA1</i>and 3820<i>BRCA2</i>female (5046 unaffected 4810 with or ovarian both at baseline) recruited in 1997-2011...
Context Screening for ovarian cancer with antigen 125 (CA-125) and transvaginal ultrasound has an unknown effect on mortality.Objective To evaluate the of screening mortality in Prostate, Lung, Colorectal Ovarian (PLCO) Cancer Trial.Design, Setting, Participants Randomized controlled trial 78 216 women aged 55 to 74 years assigned undergo either annual (n=39 105) or usual care 111) at 10 centers across United States between November 1993 July 2001.Intervention The intervention group was...
The prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was undertaken to determine whether there is a reduction in cancer mortality from screening using serum prostate-specific antigen (PSA) testing digital rectal examination (DRE). Mortality after 7–10 years follow-up has been reported previously. We report extended 13 trial. A total 76 685 men, aged 55–74 years, were enrolled at 10 centers between November 1993 July 2001 randomly assigned...
The benefits of endoscopic testing for colorectal-cancer screening are uncertain. We evaluated the effect with flexible sigmoidoscopy on incidence and mortality.
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely variants associated with increased risk breast, ovarian, pancreatic cancer recommended approaches to genetic testing/counseling management strategies in individuals these variants. This manuscript focuses BRCA-related breast/ovarian syndrome Li-Fraumeni syndrome. Carriers a BRCA1/2 variant have an excessive both breast ovarian that warrants...
The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations genetic testing counseling hereditary cancer syndromes risk management patients who are diagnosed with a syndrome. focus on associated an increased of breast and/or ovarian cancer. panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data publications abstracts, reevaluate update recommendations....
All cancers develop as a result of mutations in certain genes, such those involved the regulation cell growth and/or DNA repair, 1,2 but not all these are inherited from parent.For example, sporadic can occur somatic/ tumor cells only, and de novo for first time germ (i.e., egg or sperm) fertilized itself during early embryogen-
The effect on mortality of screening for lung cancer with modern chest radiographs is unknown.To evaluate the using in Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.Randomized controlled trial that involved 154,901 participants aged 55 through 74 years, 77,445 whom were assigned to annual screenings 77,456 usual care at 1 10 centers across United States between November 1993 July 2001. data from a subset eligible National Lung Trial (NLST), which compared radiograph...
PURPOSE Previous studies of mutations in BRCA1 or BRCA2 have used detection methods that may underestimate the actual frequency and analyzed women using heterogeneous criteria for risk hereditary cancer. PATIENTS AND METHODS A total 238 with breast cancer before age 50 ovarian at any least one first- second-degree relative either diagnosis underwent sequence analysis followed by (except 27 who declined after a deleterious mutation was discovered BRCA1). Results were correlated personal...
Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists.
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations genetic testing counseling hereditary cancer syndromes, risk management patients who are diagnosed with syndromes associated an increased of these cancers. panel meets at least annually to review comments, examine relevant new data, reevaluate update recommendations. These Insights summarize the panel’s discussion most recent regarding criteria high-penetrance genes breast...
BACKGROUND As panel testing becomes more common in clinical practice, it is important to understand the prevalence and trends associated with pathogenic variants (PVs) identified. This especially true for genetically heterogeneous cancers, such as breast cancer (BC), which PVs different genes may be various risks subtypes. The authors evaluated outcomes of genetic among women who had a personal history BC. METHODS A total 35,409 single diagnosis BC underwent 25‐gene were included current...
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations genetic testing counseling risk assessment management hereditary cancer syndromes. focus on syndromes associated with an increased of breast and/or ovarian are intended to assist clinical shared decision-making. These Insights summarize major discussion points the 2015 panel meeting. Major topics this year included multigene testing, less common mutations, salpingectomy reduction. also...
The prevalence and spectrum of germline mutations in BRCA1 BRCA2 have been reported single populations, with the majority reports focused on White Europe North America. Consortium Investigators Modifiers BRCA1/2 (CIMBA) has assembled data 18,435 families 11,351 ascertained from 69 centers 49 countries six continents. This study comprehensively describes characteristics 1,650 unique 1,731 deleterious (disease-associated) identified CIMBA database. We observed substantial variation mutation...
Models that recapitulate the complexity of human tumors are urgently needed to develop more effective cancer therapies. We report a bank patient-derived xenografts (PDXs) and matched organoid cultures from represent greatest unmet need: endocrine-resistant, treatment-refractory metastatic breast cancers. leverage PDXs PDX-derived organoids (PDxO) for drug screening is feasible cost-effective with in vivo validation. Moreover, we demonstrate feasibility using these models precision oncology...